We understand that sustainable weight loss and metabolic health management should be achieved through science, empathy, and a transparent approach
The specific magnitude and speed of this regain with retatrutide are unknown
Use of GLP-1 agonists compared with bupropion-naltrexone was associated with increased risk of pancreatitis (adjusted HR, 9.09 [95% CI, 1.25-66.00]), bowel obstruction (HR, 4.22 [95% CI, 1.02-17.40]), and gastroparesis (HR, 3.67 [95% CI, 1.15-11.90) but not biliary disease (HR, 1.50 [95% CI, 0.89-2.53])
Because of this, compounded GLP-1s arent subject to the same rigorous safety standards as FDA-approved Zepbound and Wegovy
Half a shake later
PlexusDx's Precision Peptide Genetic Test identifies variants in GLP1R and other peptide pathways that may influence how intensely your gut responds to semaglutide, helping your provider anticipate and manage these effects proactively